candesartan cilexetil has been researched along with Acute Disease in 3 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study was designed to assess the safety of modest blood pressure reduction by candesartan cilexetil in the early treatment of stroke." | 9.10 | The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. ( Berger, J; Diener, HC; Dominiak, P; Einhäupl, K; Kulschewski, A; Lüders, S; Schrader, J; Treib, J; Zidek, W, 2003) |
| "The Challenge-Stroke study was conducted in Japanese patients initiated on candesartan cilexetil therapy within 3 months of suffering a stroke to investigate the clinical use of candesartan and its efficacy/safety in this therapeutic setting." | 7.77 | Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study. ( Minematsu, K; Nakagawara, J; Okada, Y; Tanahashi, N, 2011) |
| "The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study was designed to assess the safety of modest blood pressure reduction by candesartan cilexetil in the early treatment of stroke." | 5.10 | The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. ( Berger, J; Diener, HC; Dominiak, P; Einhäupl, K; Kulschewski, A; Lüders, S; Schrader, J; Treib, J; Zidek, W, 2003) |
| "The Challenge-Stroke study was conducted in Japanese patients initiated on candesartan cilexetil therapy within 3 months of suffering a stroke to investigate the clinical use of candesartan and its efficacy/safety in this therapeutic setting." | 3.77 | Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study. ( Minematsu, K; Nakagawara, J; Okada, Y; Tanahashi, N, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanahashi, N | 1 |
| Nakagawara, J | 1 |
| Okada, Y | 1 |
| Minematsu, K | 1 |
| Schrader, J | 1 |
| Lüders, S | 1 |
| Kulschewski, A | 1 |
| Berger, J | 1 |
| Zidek, W | 1 |
| Treib, J | 1 |
| Einhäupl, K | 1 |
| Diener, HC | 1 |
| Dominiak, P | 1 |
| Murakami, M | 1 |
| Inada, Y | 1 |
| Tazawa, S | 1 |
| Nakao, K | 1 |
| Komatsu, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)[NCT00108706] | Phase 4 | 50 participants | Interventional | 2004-12-31 | Active, not recruiting | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for candesartan cilexetil and Acute Disease
| Article | Year |
|---|---|
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
Topics: Acute Disease; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2003 |
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
Topics: Acute Disease; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2003 |
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
Topics: Acute Disease; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2003 |
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
Topics: Acute Disease; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2003 |
2 other studies available for candesartan cilexetil and Acute Disease
| Article | Year |
|---|---|
Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2011 |
Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventric
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardio | 1997 |